Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; William Blair Comments on Miss
August 01, 2013 at 12:02 PM EDT
Sales of Astellas prostate cancer drug Xtandi were reported at $82 million within the US earlier, bringing down shares of Medivation (NASDAQ: MDVN ) Thursday morning. An analyst at William Blair issued a note this morning highlighting the result for Xtandi as lower than the firm's estimates for both
